Blood test may predict which lung cancer patients will respond to treatment
NCT ID NCT07244016
Summary
This study aims to see if a new blood analysis technology can predict how well patients with advanced small cell lung cancer will respond to a standard first-line treatment. The treatment combines an immunotherapy drug (tislelizumab) with chemotherapy. Researchers will analyze blood samples from 40 patients to look for patterns that might indicate who will benefit most from this therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hosipital
RECRUITINGZhengzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.